PYRGF vs. EDIT, LRMR, CRGX, AVTE, MDWD, CRBU, ENGN, ELDN, IPHA, and VTYX
Should you be buying PyroGenesis Canada stock or one of its competitors? The main competitors of PyroGenesis Canada include Editas Medicine (EDIT), Larimar Therapeutics (LRMR), CARGO Therapeutics (CRGX), Aerovate Therapeutics (AVTE), MediWound (MDWD), Caribou Biosciences (CRBU), enGene (ENGN), Eledon Pharmaceuticals (ELDN), Innate Pharma (IPHA), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical products" industry.
PyroGenesis Canada vs. Its Competitors
Editas Medicine (NASDAQ:EDIT) and PyroGenesis Canada (NASDAQ:PYRGF) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.
PyroGenesis Canada has lower revenue, but higher earnings than Editas Medicine. PyroGenesis Canada is trading at a lower price-to-earnings ratio than Editas Medicine, indicating that it is currently the more affordable of the two stocks.
Editas Medicine has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500. Comparatively, PyroGenesis Canada has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500.
PyroGenesis Canada has a net margin of -115.14% compared to Editas Medicine's net margin of -701.06%. PyroGenesis Canada's return on equity of 0.00% beat Editas Medicine's return on equity.
Editas Medicine currently has a consensus price target of $4.70, indicating a potential upside of 88.76%. Given Editas Medicine's stronger consensus rating and higher possible upside, research analysts clearly believe Editas Medicine is more favorable than PyroGenesis Canada.
In the previous week, Editas Medicine had 1 more articles in the media than PyroGenesis Canada. MarketBeat recorded 5 mentions for Editas Medicine and 4 mentions for PyroGenesis Canada. Editas Medicine's average media sentiment score of 0.68 beat PyroGenesis Canada's score of 0.00 indicating that Editas Medicine is being referred to more favorably in the media.
71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 0.0% of PyroGenesis Canada shares are owned by institutional investors. 2.1% of Editas Medicine shares are owned by insiders. Comparatively, 47.7% of PyroGenesis Canada shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Editas Medicine beats PyroGenesis Canada on 11 of the 17 factors compared between the two stocks.
Get PyroGenesis Canada News Delivered to You Automatically
Sign up to receive the latest news and ratings for PYRGF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PYRGF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PYRGF vs. The Competition
PyroGenesis Canada Competitors List
Related Companies and Tools
This page (NASDAQ:PYRGF) was last updated on 8/8/2025 by MarketBeat.com Staff
